The technology that allows scientists to profile the entire genome of individual tumors offers new hope for discovering ways to select the best treatment for each patient's particular type of cancer. However, these profiles produce huge amounts of data, and the volume alone creates unique analytical problems.
In a study published on-line this week in the journal BMC Medical Genomics, researchers from Huntsman Cancer Institute (HCI) at the University of Utah describe a new analytical approach based on a concept called multiplicity, that can organize large amounts of varied genetic data. The method allows researchers to create three-dimensional models revealing previously unknown relationships among the genes involved with different types of cancer.
"This technique shows similar genetic profiles for different types of cancers, which could open the door to trials of already approved drugs for additional cancers," said Lewis Frey, PhD, assistant professor in the Department of Biomedical Informatics and an HCI investigator. "It can bring to light previously unknown genetic connections between different cancers, helping focus the search for cancer-causing genetic mutations. It makes whole genome data more usable for both clinical and laboratory researchers."
Stephen R. Piccolo, Ph.D., a postdoctoral research associate in the Department of Biomedical Informatics at the University of Utah, and Mary E. Edgerton, M.D., Ph.D., associate professor in the Department of Pathology at MD Anderson Cancer Center in Houston, Texas, are co-authors of the article. The study was funded in part by an Incentive Seed Grant from the University of Utah, and a National Library of Medicine training grant.
The mission of Huntsman Cancer Institute (HCI) at The University of Utah is to understand cancer from its beginnings, to use that knowledge in the creation and improvement of cancer treatments, to relieve the suffering of cancer patients, and to provide education about cancer risk, prevention, and care. HCI is a National Cancer Institute-designated cancer center, which means that it meets the highest national standards for cancer care and research and receives support for its scientific endeavors. HCI is also a member of the National Comprehensive Cancer Network (NCCN), a not-for-profit alliance of the world's leading cancer centers that is dedicated to improving the quality and effectiveness of care provided to patients with cancer.